Codexis (CDXS) vs Coherus Oncology (CHRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Coherus Oncology (CHRS) has outperformed Codexis (CDXS) over the past year, losing 40.9% versus a loss of 44.9%. Over five years, CHRS leads with a -94.1% price change compared with -95.0% for CDXS. Coherus Oncology is the larger company by market cap ($156.0 million vs $150.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDXS | CHRS |
|---|---|---|
| Share price | $1.37 | $1.01 |
| Market cap | $150.46M | $156.03M |
| 1-day change | -2.55% | -0.01% |
| YTD return | -13.50% | -28.87% |
| 1-year return | -44.92% | -40.94% |
| 5-year return | -95.02% | -94.06% |
| EPS (TTM) | $-0.33 | $-1.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.98 | $2.62 |
| 52-week low | $0.96 | $1.00 |
| Distance from 52-week high | -53.89% | -61.40% |
| Analyst consensus | buy | none |
| Avg. price target upside | +346.87% | +667.40% |
| Average volume | 1.11M | 1.15M |
| Shares outstanding | 109.51M | 154.50M |
| Employees | 146 | 144 |
| Sector | Industrials | Health Care |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Codexis in Industrials and Coherus Oncology in Health Care.
About Codexis
CDXS stock →Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
Industrials · Major Chemicals · 146 employees
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
CDXS vs CHRS FAQ
Which is bigger, Codexis or Coherus Oncology?
Coherus Oncology (CHRS) is larger, with a market capitalization of $156.03M compared with $150.46M for Codexis (CDXS).
Which stock has performed better over the past year, CDXS or CHRS?
CHRS returned -40.94% over the past 12 months, compared with -44.92% for CDXS (price return, excluding dividends). Past performance does not predict future results.
Are Codexis and Coherus Oncology in the same industry?
No. Codexis is in the Industrials sector, while Coherus Oncology is in Health Care.